
    
      Part 1 - the double-blind part: The active medication arm will be given co-administration of
      0.5 mg tesofensine/50 mg metoprolol daily for 24 weeks. The placebo arm will receive matching
      placebo tablets.

      Part 2 - the open-label extension part: All active participants at the end of the
      double-blind part will be given the active medication 0.5 mg tesofensine/50 mg metoprolol
      daily for 24 weeks.
    
  